Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Therapy for chronic hepatitis C

G L Davis1, J Y Lau, H L Lim

  • 1Section of Hepatobiliary Diseases, University of Florida College of Medicine, Gainesville.

Gastroenterology Clinics of North America
|September 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Visual supplementation is an effective tool in cataract surgery counselling by eye-care practitioners.

Journal francais d'ophtalmologie·2024
Same author

European survey on the current surveillance practices, management guidelines, treatment pathways and heterogeneity of testing of Clostridioides difficile, 2018-2019: results from The Combatting Bacterial Resistance in Europe CDI (COMBACTE-CDI).

The Journal of hospital infection·2022
Same author

Prevalence of smoking and its associated factors with smoking among elderly smokers in Malaysia: findings from a nationwide population-based study.

Tobacco induced diseases·2016
Same author

Experimental study of the potential hazards of surgical smoke from powered instruments.

The British journal of surgery·2015
Same author

Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a Phase II trial.

Journal of viral hepatitis·2014
Same author

Limiting hepatitis C virus progression in liver transplant recipients using sirolimus-based immunosuppression.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2011
Same journal

Living Donor Intestinal and Liver Transplantation.

Gastroenterology clinics of North America·2026
Same journal

Living Abdominal Organ Donation: A Plan B That Saves Lives.

Gastroenterology clinics of North America·2026
Same journal

Long-Term Outcomes of Living Liver Donors.

Gastroenterology clinics of North America·2026
Same journal

Perioperative Management of Living Liver Donor Patients.

Gastroenterology clinics of North America·2026
Same journal

Living Donor Liver Transplantation for Colorectal Cancer Liver Metastasis.

Gastroenterology clinics of North America·2026
Same journal

Living Donor Liver Graft in Adult Populations: Donor Selection and Workup.

Gastroenterology clinics of North America·2026
See all related articles

Hepatitis C treatment with interferon alfa often requires long-term management, not just a 6-month course. The goal should be sustained viral suppression and disease control, as initial responses are frequently temporary.

Area of Science:

  • Hepatology
  • Virology
  • Immunology

Background:

  • Hepatitis C emerged as a significant public health issue in the 1970s and 1980s.
  • Interferon alfa is the primary therapeutic agent for Hepatitis C.
  • The long-term progression of Hepatitis C varies among individuals.

Purpose of the Study:

  • To re-evaluate the goals and expectations of interferon alfa therapy for chronic Hepatitis C.
  • To emphasize the need for long-term disease management strategies.
  • To highlight the limitations of short-term interferon treatment.

Main Methods:

  • Review of existing clinical data on Interferon alfa treatment outcomes for Hepatitis C.
  • Analysis of relapse rates and long-term efficacy of Interferon alfa therapy.

Related Experiment Videos

  • Assessment of disease progression in chronic Hepatitis C patients.

    • Main Results:

    • A single 6-month course of Interferon alfa yields limited long-term benefits for most chronic Hepatitis C patients.
    • A significant proportion of patients who initially respond to Interferon alfa experience relapse.
    • Sustained viral suppression often necessitates extended Interferon treatment durations.

    Conclusions:

    • Current treatment paradigms for Hepatitis C require adjustment, moving beyond the concept of a finite 6-month therapy.
    • The primary objective of Hepatitis C treatment should shift towards long-term control of biochemical, virologic, and histologic markers.
    • Further clinical research is essential to identify optimal therapeutic regimens for sustained Hepatitis C management.